biotech stock news October 2026
Hemostemix Wins Full LARTA Approval for Commercial VesCell Phase 1 Study
Hemostemix sold its newest units for five Canadian cents apiece. The same October 7 release disclosed full approval from a regulator in The Bahamas to begin a commercial study of VesCell, the company’s stem cell therapy. One document carries both facts, and neither one cancels the other. Hemostemix Receives Full LARTA Approval for VesCell Phase…
Hemostemix Secures Full LARTA Approval for Its VesCell Study in The Bahamas
C$0.05 a unit. That is the price Hemostemix set for new investors on October 7, in the same release that announced full approval to run its lead cell therapy study in The Bahamas. Further down that release, the company disclosed that a manufacturing license deal it first announced in February 2025 will not go ahead.…
Marvel Biosciences Closes $1.6 Million Raise to Fund MB-204 Phase 1 Deposit
Marvel Biosciences priced its units at 15 cents and asked investors for up to $3 million. It closed with $1.6 million, after a first closing originally expected around August 14 slid to the end of September. The money pays the deposit on a trial the company once expected to begin in the second quarter. Marvel…
